Name | Source | Ver | Description |
Allgemeine und neurologische Anamnese | fhir.qpath4ms#current | R4 | PlanDefinition zur allgemeinen und neurologischen Anamnese |
Allgemeine und neurologische Untersuchung | fhir.qpath4ms#current | R4 | PlanDefinition zur allgemeinen und neurologischen Untersuchung |
ANC.B Routine contact | who.fhir.anc-cds#current | R4 | To counsel and provide ANC services to a pregnant woman |
ANC.DT.01 Danger signs | who.fhir.anc-cds#current | R4 | Before each contact, during the Quick Check, the health worker should check whether the woman has any of the danger signs listed here – if yes, she should be referred to the hospital urgently; if no, the normal contact should be continued as normal |
ANC.DT.01 Danger signs | example.fhir.uv.mycontentig#current | R4 | Before each contact, during the Quick Check, the health worker should check whether the woman has any of the danger signs listed here – if yes, she should be referred to the hospital urgently; if no, the normal contact should be continued as normal |
ANC.DT.02 Adolescent HEADSS asessement | who.fhir.anc-cds#current | R4 | If client is an adolescent, conduct Home-Eating-Activity-Drugs-Sexuality-Safety-Suicide (HEADSS) assessment |
ANC.DT.03 Check symptoms and follow up | who.fhir.anc-cds#current | R4 | Depending on current and/or persistant symptoms, physiological symptoms counselling may be required |
ANC.DT.04 Conducting physical exams | who.fhir.anc-cds#current | R4 | Depending on the results of some physical exams, additional examinations or repeat measurements are required |
ANC.DT.05 Evaluating labour | who.fhir.anc-cds#current | R4 | During a cervical exam, if cervical dilation is greater than 2 cm evaluate the possibility of labour |
ANC.DT.06 Physical symptoms and exam results requiring referral | who.fhir.anc-cds#current | R4 | If the woman has any of the following physical exam results, refer to the hospital |
ANC.DT.07 Ultrasound recommendation | who.fhir.anc-cds#current | R4 | An ultrasound is recommended for all pregnant women before 24 weeks of gestation (early ultrasound). If there's no ultrasound available at that health-carte facility, the woman should be referred to another facility in which she can receive an ultrasound. |
ANC.DT.08 HIV testing | who.fhir.anc-cds#current | R4 | Depending on the population prevalence, and woman's medical history, conduct HIV testing |
ANC.DT.09 Heptatitis B testing | who.fhir.anc-cds#current | R4 | Depending on the population prevalence, and woman's medical history, conduct hepatitis B testing |
ANC.DT.10 Hepatitis C testing | who.fhir.anc-cds#current | R4 | Depending on the population prevalence, and woman's medical history, conduct hepatitis C testing |
ANC.DT.11 Syphilis testing | who.fhir.anc-cds#current | R4 | Depending on the contact schedule, and woman's syphilis diagnosis, test for syphilis |
ANC.DT.12 Urine testing | who.fhir.anc-cds#current | R4 | Conditions in which urine testing is required |
ANC.DT.13 Tuberculosis screening | who.fhir.anc-cds#current | R4 | Conditions in which screening for TB is recommended |
ANC.DT.14 Other | who.fhir.anc-cds#current | R4 | Additional blood tests |
ANC.DT.15 Behaviour counselling required | who.fhir.anc-cds#current | R4 | Depending on the woman's behaviours reported during the first contact and the woman's reported persistent behaviours, additional counselling may or may not be required |
ANC.DT.16 Dietary counselling | who.fhir.anc-cds#current | R4 | ALL women should have "Healthy eating and keeping physically active counselling" with guidance on nutrition and exercise. If a woman is classified as "underweight" AND she is part of a population whereby the prevalence of undernourishment is greater than or equal to 20%, then additional dietary counselling is needed. |
ANC.DT.17 Pre-eclampsia, severe pre-eclampsia and hypertension diagnosis | who.fhir.anc-cds#current | R4 | If the woman presents with any of the following symptoms and/or test results, conduct counselling and referral as needed |
ANC.DT.18 HIV diagnosis | who.fhir.anc-cds#current | R4 | If the woman tests positive for HIV, provide counselling and referral as needed |
ANC.DT.19 Hepatitis B diagnosis | who.fhir.anc-cds#current | R4 | If the woman tests positive for hepatitis B, provide counselling and referral as needed |
ANC.DT.20 Hepatitis C diagnosis | who.fhir.anc-cds#current | R4 | If the woman tests positive for hepatitis C, provide counselling and referral as needed |
ANC.DT.21 Syphilis diagnosis | who.fhir.anc-cds#current | R4 | If the woman tests positive for syphilis, provide counselling and treatment as needed |
ANC.DT.22 Asymptomatic bacteriuria (ASB) diagnosis | who.fhir.anc-cds#current | R4 | If the woman tests positive for ASB, provide counselling and treatment as needed. |
ANC.DT.23 Gestational diabetes mellitus (GDM) and diabetes mellitus (DM) during pregnancy diagnosis | who.fhir.anc-cds#current | R4 | If the woman's blood glucose test results are as follows, provide the necessary counselling and treatment |
ANC.DT.24 TB diagnosis | who.fhir.anc-cds#current | R4 | If the woman's TB screening results are positive for TB, provide the required treatment as per local TB protocols |
ANC.DT.25 Anaemia, iron and folic acid supplementation | who.fhir.anc-cds#current | R4 | Testing for anaemia is recommended for all pregnant women. Regardless of test results, iron and folic acid supplementation is recommended. The amount of iron and folic acid supplementation will vary depending on anaemia diagnosis, population prevalence of anaemia, and whether the woman has side-effects due to iron and folic acid supplementation. |
ANC.DT.26 Calcium and vitamin A supplementation | who.fhir.anc-cds#current | R4 | Depending on the population, additional calcium and/or vitamin A supplements maybe required |
ANC.DT.27 Pre-eclampsia risk counselling | who.fhir.anc-cds#current | R4 | If the woman has risk factors for developing pre-eclampsia, provide counselling to reduce risk of developing pre-eclampsia |
ANC.DT.28 Gestational diabetes mellitus (GDM) risk counselling | who.fhir.anc-cds#current | R4 | If the woman has risk factors for developing gestational diabetes mellitus (GDM), provide counselling to reduce risk of developing GDM |
ANC.DT.29 HIV risk counselling | who.fhir.anc-cds#current | R4 | If the woman has risk factors for contracting HIV, provide counselling to reduce risk of contracting HIV |
ANC.DT.30 General risk reduction counselling | who.fhir.anc-cds#current | R4 | Depending on a variety of risk factors and/or gestational age, provide additional counselling accordingly |
ANC.DT.31 Flu immunization | who.fhir.anc-cds#current | R4 | If the woman has not yet been immunized with the seasonal flu vaccine, she should be immunized |
ANC.DT.32 Tetanus toxoid-containing vaccination | who.fhir.anc-cds#current | R4 | If the woman has not yet been fully immunized against tetanus, she should be immunized |
ANC.DT.33 Breastfeeding counselling | who.fhir.anc-cds#current | R4 | General counselling to be provided/reviewed at every contact |
ANC.DT.34 Birth preparedness counselling | who.fhir.anc-cds#current | R4 | General counselling to be provided/reviewed at every contact |
ANC.DT.35 Family planning counselling | who.fhir.anc-cds#current | R4 | General counselling to be provided/reviewed at every contact |
ANC.DT.36 Intimate partner violence (IPV) clinical inquiry | who.fhir.anc-cds#current | R4 | You may suspect that a woman has been subjected to intimiate partner violence if she has any of the following risk factors |
ANC.DT.37 Intimate partner violence (IPV) first-line support and treatment | who.fhir.anc-cds#current | R4 | Woman has been subjected to IPV |
ANC.DT.38 Deworming and malaria prophylaxis | who.fhir.anc-cds#current | R4 | IF the woman is currently in a malaria-endemic setting, or in an area where there is greater than 20% prevalence of infection with any soil-transmitted helminths, THEN she should receive preventative treatment accordingly |
ANC.S.01 Contact schedule | who.fhir.anc-cds#current | R4 | To counsel and provide ANC services to a pregnant woman |
Arztvorstellung | fhir.qpath4ms#current | R4 | PlanDefinition zur Arztvorstellung |
Auswertung | fhir.qpath4ms#current | R4 | PlanDefinition zur Auswertung |
Basismonitoring - Besuch M3 / M9 | fhir.qpath4ms#current | R4 | PlanDefinition zum Basismonitoring-Patientepfad zum Besuchstermin im 3./9. Monat |
Basismonitoring - Besuch M6 | fhir.qpath4ms#current | R4 | PlanDefinition zum Basismonitoring-Patientepfad zum Besuchstermin im 6. Monat |
Basismonitoring - M0 | fhir.qpath4ms#current | R4 | PlanDefinition zum Basismonitoring-Patientepfad zum Besuchstermin im 0. Monat |
Basismonitoring Patientenpfad - 1 Jahreszyklus | fhir.qpath4ms#current | R4 | PlanDefinition zum Basismonitoring-Patientenpfad für einen Jahreszyklus |
Befundauswertung | fhir.qpath4ms#current | R4 | PlanDefinition zur Befundauswertung |
BgZ 2017 | hl7.fhir.nl.zorgviewer#current | R3 | |
Check-In | fhir.qpath4ms#current | R4 | PlanDefinition zum Check-In |
Check-Out | fhir.qpath4ms#current | R4 | PlanDefinition zum Check-Out |
Colorectal Cancer Screening CDS | fhir.cqf.ccc#current | R4 | |
Ganganalyse | fhir.qpath4ms#current | R4 | PlanDefinition zur Ganganalyse |
Hello HIV World | fhir.nachc.hiv-cds#current | R4 | This PlanDefinition defines a simple recommendation handling the sampling of HIV |
High Blood Pressure Warning | hl7.fhir.us.ohsuhypertensionig#current | R4 | This PlanDefinition detects a recent high blood pressure reading. |
Hypertension Diagnosis | hl7.fhir.us.ohsuhypertensionig#current | R4 | This PlanDefinition looks for indications a patient should be diagnosed with hypertension. |
IMMZ.DT.01.BCG | who.fhir.immunization#current | R4 | If child or person has not been vaccinated, give BCG vaccine as soon as possible after birth |
IMMZ.DT.02.HepatitisB | who.fhir.immunization#current | R4 | If child or person has not been vaccinated, give Hepatitis B vaccine as soon as possible after birth |
IMMZ.DT.03.Polio | who.fhir.immunization#current | R4 | If child or person has not been vaccinated, give Polio vaccine |
IMMZ.DT.04.DTP | who.fhir.immunization#current | R4 | If child or person has not been given DTP, start scheme |
IMMZ.DT.05.Hib | who.fhir.immunization#current | R4 | if child or person has not been vaccinated, give Hib vaccine between 6 weeks and 59 months |
IMMZ.DT.06.Pneumococcal | who.fhir.immunization#current | R4 | If child or person has not been vaccinated, give Pneumococcal vaccine minimum age 6 weeks old |
IMMZ.DT.07.Rotavirus | who.fhir.immunization#current | R4 | If child or person has not been vaccinated, give Rotavirus vaccine according to the defined schedule |
IMMZ.DT.08.Measles | who.fhir.immunization#current | R4 | If the child or patient has not been given MCV1 (at 9 months) and MCV2 (between 15-18 months) vaccination |
IMMZ.DT.09.Rubella | who.fhir.immunization#current | R4 | If child or patient has not received the Rubella vaccination and is greater than or equal to 9 months |
IMMZ.DT.10.HPV | who.fhir.immunization#current | R4 | If child or person has not been vaccinated, give HPV vaccine according to the defined schedule |
IMMZ.DT.11.JapaneseEncephalitis | who.fhir.immunization#current | R4 | If child or person has not been vaccinated, give Japanese Encephalitis vaccine according to the defined schedule |
IMMZ.DT.12.YellowFever | who.fhir.immunization#current | R4 | If child or person has not been vaccinated, give Yellow Fever vaccine between age 9-12 months |
IMMZ.DT.13.Tick-BorneEncephalitis | who.fhir.immunization#current | R4 | If child or person has not been vaccinated, give Tick-Borne Encephalitis vaccine according to the defined schedule |
IMMZ.DT.14.Typhoid | who.fhir.immunization#current | R4 | If child or person has not been vaccinated, give the Typhoid vaccine between age 6 months - 45 years old |
IMMZ.DT.15.Cholera | who.fhir.immunization#current | R4 | If child or person has not been vaccinated, give the Cholera vaccine to child greater than or equal to 1 year old and adults |
IMMZ.DT.16.Meningococcal | who.fhir.immunization#current | R4 | If child or person has not been vaccinated, give Meningococcal vaccine according to the defined schedule |
IMMZ.DT.17.HepatitisA | who.fhir.immunization#current | R4 | If child or person has not been vaccinated, give Hepatitis A vaccine at 1 year of age |
IMMZ.DT.18.Rabies | who.fhir.immunization#current | R4 | If patient has not been vaccinated, give Rabies vaccine |
IMMZ.DT.19.Dengue | who.fhir.immunization#current | R4 | If child or person has not been vaccinated, give Dengue vaccine between 9 and 45 years of age |
IMMZ.DT.20.Mumps | who.fhir.immunization#current | R4 | If child or person has not been vaccinated against Mumps, give Mumps vaccine |
IMMZ.DT.21.SeasonalInfluenza | who.fhir.immunization#current | R4 | If child or person has not been vaccinated, give Seasonal Influenza vaccine at 6 months of age, and then once a year. |
IMMZ.DT.22.Varicella | who.fhir.immunization#current | R4 | If child or person has not been vaccinated against Varicella |
Laboruntersuchung | fhir.qpath4ms#current | R4 | PlanDefinition zur Laboruntersuchung |
Magnetresonanztomographie | fhir.qpath4ms#current | R4 | PlanDefinition zur Magnetresonanztomographie (MRT) |
Monitoring | hl7.fhir.us.ohsuhypertensionig#current | R4 | This PlanDefinition provides patient recommendations for monitoring a preexisting Hypertension condition. |
Multiple Sclerosis Performance Test | fhir.qpath4ms#current | R4 | PlanDefinition zum Multiple Sclerosis Performance Test (MSPT) |
NACHC HIV Screening | fhir.nachc.hiv-cds#current | R4 | This PlanDefinition defines a Clinical Decision Support rule to determine whether HIV Screening is appropriate based on CDC Recommendations for HIV Screening |
Optische Kohärenztomographie | fhir.qpath4ms#current | R4 | PlanDefinition zur Optischen Kohärenztomographie (OCT) |
PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #1 | fhir.cdc.opioid-cds-r4#current | R4 | Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for subacute or chronic pain. |
PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #10 | fhir.cdc.opioid-cds-r4#current | R4 | When prescribing opioids for subacute or chronic pain, providers should use urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs. |
PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #10 (order-sign) | fhir.cdc.opioid-cds-r4#current | R4 | When prescribing opioids for subacute or chronic pain, providers should use urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs. |
PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #10 (patient-view) | fhir.cdc.opioid-cds-r4#current | R4 | When prescribing opioids for subacute or chronic pain, providers should use urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs. |
PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #11 | fhir.cdc.opioid-cds-r4#current | R4 | Concurrently prescribing opioid medications with benzodiazepines increases the risk of harm for the patient. |
PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #11 (patient-view) | fhir.cdc.opioid-cds-r4#current | R4 | Concurrently prescribing opioid medications with benzodiazepines increases the risk of harm for the patient. |
PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #12 (patient-view) | fhir.cdc.opioid-cds-r4#current | R4 | Arrange evidence-based treatment (usually medication-assisted treatment with buprenorphine or methadone in combination with behavioral therapies) for patients with opioid use disorder. |
PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #2 | fhir.cdc.opioid-cds-r4#current | R4 | Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic pain. |
PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #3 | fhir.cdc.opioid-cds-r4#current | R4 | When starting opioid therapy for subacute or chronic pain, clinicians should prescribe immediate-release opioids instead of extended-release/long-acting (ER/LA) opioids. |
PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #6 | fhir.cdc.opioid-cds-r4#current | R4 | When opioids are used for acute pain, clinicians should prescribe the lowest effective dose of immediate-release opioids and should prescribe no greater quantity than needed for the expected duration of pain severe enough to require opioids. |
PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #7 | fhir.cdc.opioid-cds-r4#current | R4 | Clinicians should evaluate benefits and harms with patients within 1 to 4 weeks of starting opioid therapy for subacute or chronic pain or of dose escalation. Clinicians should evaluate benefits and harms of continued therapy with patients every 3 months or more frequently. |
PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #8 | fhir.cdc.opioid-cds-r4#current | R4 | Clinicians should incorporate into the management plan strategies to mitigate risk, including considering offering naloxone when factors that increase risk for opioid overdose, such as history of overdose, history of substance use disorder, higher opioid dosages (≥50 MME/day), or concurrent benzodiazepine use, are present. |
PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #8 (order-sign) | fhir.cdc.opioid-cds-r4#current | R4 | Clinicians should incorporate into the management plan strategies to mitigate risk, including considering offering naloxone when factors that increase risk for opioid overdose, such as history of overdose, history of substance use disorder, higher opioid dosages (≥50 MME/day), or concurrent benzodiazepine use, are present. |
PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #9 | fhir.cdc.opioid-cds-r4#current | R4 | Clinicians should review PDMP data when starting opioid therapy for subacute or chronic pain and periodically during opioid therapy for chronic pain. |
PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendations #4 and #5 | fhir.cdc.opioid-cds-r4#current | R4 | When opioids are started, providers should prescribe the lowest effective dosage. |
Potential Adverse Reaction Detection | hl7.fhir.us.ohsuhypertensionig#current | R4 | This PlanDefinition detects recent adverse reactions that could be related to Hypertension medication. |
Template for COVID-19 Care in the Community CCCM MVP Careplans | cinc.fhir.ig#current | R4 | Creates a care plan suitable for a low to medium-risk COVID-19 case: patient activities include medication delivery, heath checks, RAT self-test and follow-up GP Check |
Terminvereinbarung | fhir.qpath4ms#current | R4 | PlanDefinition zur Terminvereinbarung |
Therapiespezifische Diagnostik | fhir.qpath4ms#current | R4 | PlanDefinition zur therapiespezifischen Diagnostik |
Therapy - Medicines | hl7.fhir.us.ohsuhypertensionig#current | R4 | This PlanDefinition provides pharmacologic recommendations for patients with Hypertension |
Therapy - Non-medicinal | hl7.fhir.us.ohsuhypertensionig#current | R4 | This PlanDefinition identifies Non-Pharmacologic Interventions for Hypertension |
Voruntersuchungen | fhir.qpath4ms#current | R4 | PlanDefinition zu Voruntersuchungen |
Voruntersuchungen | fhir.qpath4ms#current | R4 | PlanDefinition zu Voruntersuchungen (M3 + M9) |
Voruntersuchungen | fhir.qpath4ms#current | R4 | PlanDefinition zu Voruntersuchungen (M6) |
Zusatzdiagnostik | fhir.qpath4ms#current | R4 | PlanDefinition zur Zusatzdiagnostik |
Produced 08 Sep 2023